Advice

following a full submission:

buprenorphine (BuvidalĀ®) is accepted for restricted use within NHSScotland.

Indication under review: Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over.

SMC restriction: Use in patients in whom methadone is not suitable and for whom the use of buprenorphine is considered appropriate.

In a phase III study in patients with opioid dependence, subcutaneous buprenorphine was non-inferior to sublingual buprenorphine/naloxone for the mean percentage of urine samples with test results negative for illicit opioids.

Medicine details

Medicine name:
buprenorphine (Buvidal)
SMC ID:
SMC2169
Indication:

For the treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over.

Pharmaceutical company
Camurus Ltd
BNF chapter
Central nervous system
Submission type
Full
Status
Restricted
Date advice published:
12 August 2019